Hayfever Relief For Adults

Hayfever Relief For Adults is a nasal formulation containing the corticosteroid beclometasone dipropionate. Marketed in the European Union, this product is designed for adult use to manage symptoms of allergic rhinitis, commonly known as hay fever. It is administered as a nasal spray, delivering the active ingredient directly to the nasal mucosa to help control inflammation associated with seasonal allergies and improve quality of life.

Hayfever Relief For Adults is indicated for the symptomatic treatment of allergic rhinitis in adults.

- Relief of nasal congestion, sneezing and itching caused by seasonal allergens. - Management of persistent or intermittent hay‑fever symptoms when avoidance measures are insufficient. - Adjunct therapy for patients who have not achieved adequate control with oral antihistamines alone. - Use as part of a comprehensive allergy management plan, including environmental control.

Side effects reported with beclometasone dipropionate nasal spray are generally mild, but serious reactions can occur.

Common: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Minor nosebleeds (epistaxis). - Throat irritation or cough.

Serious: - Signs of adrenal suppression such as fatigue, weakness or unexplained weight loss. - Severe or persistent nosebleeds. - Allergic reactions including swelling of the face, lips or throat, and difficulty breathing.

Before using Hayfever Relief For Adults, consider the following precautions to ensure safe and effective treatment.

- Do not use if you have a known hypersensitivity to beclometasone dipropionate or any other component of the spray. - Limit use to the recommended duration; prolonged therapy may increase the risk of local or systemic corticosteroid effects. - Monitor for signs of nasal septum perforation, especially with excessive or improper administration. - Caution in patients with uncontrolled diabetes, glaucoma, or cataracts, as corticosteroids can exacerbate these conditions. - Discuss use with a healthcare professional during pregnancy or breastfeeding; the product is classified as pregnancy category B. - Avoid use in children unless specifically prescribed, as safety and efficacy have not been established for pediatric populations.

Beclometasone dipropionate may interact with other medications; review the following categories.

Avoid: - Concurrent use of potent systemic corticosteroids (e.g., oral prednisolone) that could increase systemic glucocorticoid exposure. - Nasal decongestant sprays containing oxymetazoline or phenylephrine when used excessively, which may worsen nasal mucosal irritation.

Use with caution: - Antifungal agents such as ketoconazole that inhibit CYP3A4 and could raise local steroid levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) that may reduce the effectiveness of the nasal steroid. - Immunosuppressive drugs, including biologics, where additional immunosuppression could increase infection risk. - Vaccines, particularly live attenuated vaccines, as systemic absorption of steroids might diminish immune response.